Literature DB >> 6186318

The expression of myeloid-specific antigens on myeloid leukemia cells: correlations with leukemia subclasses and implications for normal myeloid differentiation.

E D Ball, M W Fanger.   

Abstract

The expression of three distinct myeloid-specific cell surface antigens detected by monoclonal antibodies (PMN 6, PMN 29, and AML-2-23) on acute and chronic myeloid leukemia cells is correlated with blast cell morphology and normal myeloid cell antigen display. In studies on normal peripheral blood cells, monoclonal antibodies PMN 6 and PMN 29 have previously been shown to react exclusively with neutrophils while AML-2-23 reacts with both neutrophils and monocytes. The present report demonstrates that these antigens are absent from blast cells of patients with acute myelocytic leukemia (AML) classified as M1 and M2 in the French-American-British system and chronic myelocytic leukemia in myeloid blast crisis. However, leukemia cells with myelomonocytic morphology (M4) expressed all three antigens, while cells with pure monocytic features (M5) were generally only positive for AML-2-23. Based on the absence of these antigens on both leukemic and normal myeloblasts and granulocyte-monocyte progenitors and their characteristic patterns of display on more differentiated leukemic and normal cells, we propose a modified concept of normal myelopoiesis. In this hypothesis, the myeloblast is an uncommitted cell that gives rise to a series of intermediate precursors that acquire committment to either the granulocytic or monocytic lineage marked by the acquisition of specific cell surface markers.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6186318

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Application of a novel immunization protocol to the production of monoclonal antibodies specific for macrophages in human placenta.

Authors:  A D Nash; S Uren; C S Hawes; W Boyle
Journal:  Immunology       Date:  1989-11       Impact factor: 7.397

2.  Correlation of surface marker expression with morphologically and immunologically defined subclasses of acute myeloid leukaemias.

Authors:  H G Drexler; M Menon; M Klein; N Bhoopalam; H L Messmore; J Minowada
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

3.  Monocyte/macrophage-reactive monoclonal antibody Ki-M6 recognizes an intracytoplasmic antigen.

Authors:  M R Parwaresch; H J Radzun; H Kreipe; M L Hansmann; J Barth
Journal:  Am J Pathol       Date:  1986-10       Impact factor: 4.307

Review 4.  Characterization of hematopoietic stem and progenitor cells.

Authors:  D E Williams; L Lu; H E Broxmeyer
Journal:  Immunol Res       Date:  1987       Impact factor: 2.829

5.  Gamma interferon induces monocytoid differentiation in the HL-60 cell line.

Authors:  E D Ball; P M Guyre; L Shen; J M Glynn; C R Maliszewski; P E Baker; M W Fanger
Journal:  J Clin Invest       Date:  1984-04       Impact factor: 14.808

6.  Plasma membrane proteins from human normal and chronic myeloid leukemic granulocytes: identification and partial characterization of the concanavalin A-binding and detergent resistant proteins.

Authors:  S M Zingde; S H Advani; B P Gothoskar
Journal:  Blut       Date:  1987-08

7.  Definition of a possible genetic basis for susceptibility to acute myelogenous leukemia associated with the presence of a polymorphic Ia epitope.

Authors:  S Seremetis; J Cuttner; R Winchester
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

8.  Changes in surface antigens of HL-60 cells during differentiation in vitro.

Authors:  J F San Miguel; D M McCarthy; B Rodriques; H C Freake; H Zola; J M Goldman; D Catovsky
Journal:  Blut       Date:  1984-11

9.  Immune interferon and leukocyte-conditioned medium induce normal and leukemic myeloid cells to differentiate along the monocytic pathway.

Authors:  B Perussia; E T Dayton; V Fanning; P Thiagarajan; J Hoxie; G Trinchieri
Journal:  J Exp Med       Date:  1983-12-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.